Immunogenicity of Bacillus Calmette-Guérin in pigs: potential as a translational model of non-specific effects of BCG.
Actinobacillus pleuropneumoniae
BCG
heterologous immunity
influenza virus
non-specific effects
pigs
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
05
2023
accepted:
26
06
2023
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Clinical and immunological studies in humans show that the live attenuated In a series of experiments, we randomized newborn or young piglets from conventional farms to receiving BCG or placebo and investigated the persistence of live BCG bacteria in various tissues, the immunogenicity of BCG in The BCG vaccine was generally well tolerated. In contrast to humans, no skin reaction in the form of abscesses, ulcers, or scars was observed. Live BCG was recovered from draining lymph nodes in 2/13 animals 20 weeks after vaccination. Specific BCG was safe in pigs, inducing specific immunological responses, but our model did not corroborate the innate immunological responsiveness to BCG seen in humans. The dose of BCG or the bacterial and viral challenges may have been sub-optimal. Even so, the acute phase protein response to influenza infection was significantly reduced in BCG-vaccinated animals.
Sections du résumé
Background
UNASSIGNED
Clinical and immunological studies in humans show that the live attenuated
Methods
UNASSIGNED
In a series of experiments, we randomized newborn or young piglets from conventional farms to receiving BCG or placebo and investigated the persistence of live BCG bacteria in various tissues, the immunogenicity of BCG in
Results
UNASSIGNED
The BCG vaccine was generally well tolerated. In contrast to humans, no skin reaction in the form of abscesses, ulcers, or scars was observed. Live BCG was recovered from draining lymph nodes in 2/13 animals 20 weeks after vaccination. Specific
Discussion
UNASSIGNED
BCG was safe in pigs, inducing specific immunological responses, but our model did not corroborate the innate immunological responsiveness to BCG seen in humans. The dose of BCG or the bacterial and viral challenges may have been sub-optimal. Even so, the acute phase protein response to influenza infection was significantly reduced in BCG-vaccinated animals.
Identifiants
pubmed: 37520542
doi: 10.3389/fimmu.2023.1219006
pmc: PMC10374211
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1219006Informations de copyright
Copyright © 2023 Jensen, Hansen, Skovgaard, Svensson, Larsen, Heegaard, Benn and Jungersen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Res Vet Sci. 2016 Feb;104:50-2
pubmed: 26850536
BMC Vet Res. 2014 Apr 26;10:96
pubmed: 24766746
Cells. 2020 Sep 16;9(9):
pubmed: 32948003
J Intern Med. 2020 Dec;288(6):614-624
pubmed: 32301189
Fish Shellfish Immunol. 2012 Aug;33(2):243-50
pubmed: 22609413
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42
pubmed: 22988082
Vet Immunol Immunopathol. 2019 Sep;215:109884
pubmed: 31420066
Virol J. 2013 Sep 18;10:290
pubmed: 24047399
Immunobiology. 1993 Apr;187(3-5):330-45
pubmed: 8330902
Innate Immun. 2021 Aug;27(6):448-460
pubmed: 32862748
BMJ. 2016 Oct 13;355:i5170
pubmed: 27737834
Dev Comp Immunol. 2009 Mar;33(3):273-83
pubmed: 18762210
Trends Mol Med. 2022 Jun;28(6):497-512
pubmed: 35466062
Vet Immunol Immunopathol. 2011 Feb 15;139(2-4):257-63
pubmed: 20889217
Clin Immunol. 2023 Jan;246:109208
pubmed: 36565972
Cell Tissue Res. 2020 May;380(2):287-304
pubmed: 32356014
PLoS One. 2009 Aug 17;4(8):e6662
pubmed: 19684857
Cell Host Microbe. 2020 Aug 12;28(2):322-334.e5
pubmed: 32544459
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
Heliyon. 2022 Dec 15;8(12):e12356
pubmed: 36590473
Dis Model Mech. 2020 Sep 15;13(9):
pubmed: 32988990
Future Microbiol. 2018 Aug;13:1193-1208
pubmed: 30117744
PLoS One. 2014 May 19;9(5):e98048
pubmed: 24842853
PLoS One. 2012;7(4):e35549
pubmed: 22530048
Cell Rep. 2022 Mar 8;38(10):110502
pubmed: 35235831
Clin Vaccine Immunol. 2014 Jan;21(1):12-20
pubmed: 24173022
Sci Transl Med. 2020 May 6;12(542):
pubmed: 32376769
Paediatr Respir Rev. 2020 Nov;36:57-64
pubmed: 32958428
Infect Immun. 2004 Mar;72(3):1504-11
pubmed: 14977956
Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):29-41
pubmed: 28890996
Lab Anim. 2018 Dec;52(6):630-640
pubmed: 29653496
Vaccine. 2009 Nov 12;27(48):6662-8
pubmed: 19747578
Vet Immunol Immunopathol. 2006 Sep 15;113(1-2):157-68
pubmed: 16774789
Heliyon. 2021 Jan 04;7(1):e05757
pubmed: 33474505
Nat Commun. 2019 Feb 20;10(1):874
pubmed: 30787276
J Infect Dis. 2015 Mar 15;211(6):956-67
pubmed: 25210141
Immunobiology. 2022 May;227(3):152192
pubmed: 35255458
Vet Microbiol. 2009 Mar 2;134(3-4):334-9
pubmed: 19095381
Cell. 2018 Jan 11;172(1-2):176-190.e19
pubmed: 29328912
Clin Infect Dis. 2017 Oct 1;65(7):1183-1190
pubmed: 29579158
BMC Genet. 2010 Oct 15;11:94
pubmed: 20950446
J Immunol Methods. 2005 Feb;297(1-2):1-11
pubmed: 15777926
Vaccine. 2022 Mar 8;40(11):1534-1539
pubmed: 33863572
Trans R Soc Trop Med Hyg. 2015 Apr;109(4):287
pubmed: 25770252
Front Immunol. 2019 Jul 05;10:1557
pubmed: 31333678
PLoS One. 2015 Jul 14;10(7):e0132288
pubmed: 26172261
J Immunol Methods. 2009 Apr 15;343(2):112-8
pubmed: 19236874